Novo Nordisk files Ideglira for EU approval for treatment of Type 2 Diabetes
Novo Nordisk has filed for EU approval of Ideglira � a combination of its insulin degludec Tresiba and its GLP-1 analogue Victoza (liraglutide).
The filing is based on results from the DUAL clinical trial programmes, which involved around 2,000 people with Type 2 Diabetes, as well as studies involving individual Tresiba and Victoza.
Patients in this study treated once-daily with Ideglira achieved an average reduction in HbA1c (a measurement of blood sugar levels) of 1.9 per cent. In addition, 81 per cent of people previously treated with oral diabetes medicines and 60 per cent of those previously treated with basal insulin achieved the target of HbA1c of 7 per cent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.